EVAX Q3 2025 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena

EVAXEvaxion Biotech A/S

$20M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+148.3% YoY

Gross Profit

$7M100.0% margin

Operating Income

$3M40.3% margin

Net Income

$5M61.6% margin

EPS (Diluted)

$4.20

QoQ Revenue Growth

+20148.6%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$30M

Total Liabilities

$13M

Stockholders' Equity

$17M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$3M	+148.3%
Gross Profit	$7M	$3M	+148.3%
Operating Income	$3M	-$2M	+274.6%
Net Income	$5M	-$2M	+338.7%